Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dyadic International (NQ: DYAI ) 1.370 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Dyadic International < Previous 1 2 3 4 Next > Dyadic to Present at Industry Events in November October 30, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 October 25, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Appoints Doug Pace to Its Executive Leadership Team October 09, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic October 05, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Present at Industry and Investor Events in October September 29, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells September 26, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™ September 19, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Present at BioProcess International September 12, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin August 07, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023 July 26, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate July 24, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity June 21, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Participate at Upcoming Events in June June 01, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Participate at Two Industry Events in May May 10, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™ May 08, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 April 26, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform April 18, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent April 12, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Present at World Vaccine Congress Washington 2023 March 30, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023 March 15, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate March 07, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Present at Roth Investor Conference and Upcoming Industry Events March 01, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Participate in Two Upcoming Investor Conferences February 02, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate January 24, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Announces Sale of Equity Interest in Alphazyme January 19, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference January 04, 2023 Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA... From Dyadic International, Inc. Via GlobeNewswire Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal December 14, 2022 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Present at Upcoming Industry and Investor Events in November November 07, 2022 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022 October 27, 2022 From Dyadic International, Inc. Via GlobeNewswire Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate October 27, 2022 From Dyadic International, Inc. Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.